Featured Research

from universities, journals, and other organizations

Promising New Treatment For Ulcerative Colitis Sufferers

Date:
January 5, 2006
Source:
University of Kentucky
Summary:
A promising new therapy pioneered by University of Kentucky gastroenterology specialists may offer improved lives to patients suffering from moderate to severe forms of the disease.

For people with the chronic disease ulcerative colitis, life can be limited to few social functions and trips away from home.

Related Articles


A promising new therapy pioneered by University of Kentucky gastroenterology specialists may offer improved lives to patients suffering from moderate to severe forms of the disease.

Ulcerative colitis causes inflammation and ulcers in the colon, leading to abdominal pain and such frequent trips to the bathroom that normal routines can be disrupted. Finding the right treatment can be difficult, with therapies that may include steroids and anti-inflammatory drugs, or possibly surgery in as many as 25 to 40 percent of ulcerative colitis patients.

A drug already used for other inflammatory diseases, including Crohn's and rheumatoid arthritis, has received FDA approval for treatment of ulcerative colitis after performing well in clinical trials. UK was a primary investigator of infliximab, brand name Remicade®, and enrolled the largest study group in North America.

"It's a very welcome addition to our treatment options," said Willem J.S. deVilliers, M.D., Ph.D., chief of the UK Division of Digestive Diseases and Nutrition. DeVilliers co-authored a report of the trial, which was recently published in the New England Journal of Medicine.

One of the study participants is Robert Lewandowski, of Hager Hill in Johnson County. Lewandowski was diagnosed with the disease a decade ago and saw the retirement plans he and his wife made slipping away as he became more and more reluctant to leave home.

"The first thing you do is when you think about going somewhere, you have to think about where the bathroom is and how quickly you can get to it," Lewandowski said. "Eventually, you stop going and doing things because it's too much of a problem."

Lewandowski's disease went into remission after a few years, then reappeared, sending him to the bathroom 20 or more times a day. Therapies he used in the past didn't work, so his physician referred him to the clinical study at UK. He saw an improvement almost immediately, and a year later, he is able to lead a normal life, with no symptoms of the disease. "I'm happy," he said.

The medication is administered intravenously, with an initial regimen of three doses of infliximab, followed by maintenance infusions every eight weeks. Nearly 70 percent of patients receiving the drug experienced clinical response and remission early in the trial, and nearly all had significant results after one year of therapy.

For more information, contact the UK Division of Digestive Diseases and Nutrition at (859) 323-5575.


Story Source:

The above story is based on materials provided by University of Kentucky. Note: Materials may be edited for content and length.


Cite This Page:

University of Kentucky. "Promising New Treatment For Ulcerative Colitis Sufferers." ScienceDaily. ScienceDaily, 5 January 2006. <www.sciencedaily.com/releases/2006/01/060105082154.htm>.
University of Kentucky. (2006, January 5). Promising New Treatment For Ulcerative Colitis Sufferers. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2006/01/060105082154.htm
University of Kentucky. "Promising New Treatment For Ulcerative Colitis Sufferers." ScienceDaily. www.sciencedaily.com/releases/2006/01/060105082154.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com
What's Different About This Latest Ebola Vaccine

What's Different About This Latest Ebola Vaccine

Newsy (Mar. 26, 2015) — A whole virus Ebola vaccine has been shown to protect monkeys exposed to the virus. Here&apos;s what&apos;s different about this vaccine. Video provided by Newsy
Powered by NewsLook.com
HIV Outbreak Prompts Public Health Emergency In Indiana

HIV Outbreak Prompts Public Health Emergency In Indiana

Newsy (Mar. 26, 2015) — Indiana Gov. Mike Pence says he will bring additional state resources to help stop the epidemic. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins